DUBLIN–(BUSINESS WIRE)–The “Viral Vector & Plasmid DNA Manufacturing Market Intelligence Report – Global Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering.
The Global Viral Vector & Plasmid DNA Manufacturing Market is projected to reach USD 3,296.84 million by 2027 from USD 860.08 million in 2021, at a CAGR 25.10% during the forecast period.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.
- The Americas Viral Vector & Plasmid DNA Manufacturing Market size was estimated at USD 311.42 million in 2021 and expected to reach USD 388.54 million in 2022, at a CAGR 25.01% to reach USD 1,189.03 million by 2027.
- The Asia-Pacific Viral Vector & Plasmid DNA Manufacturing Market size was estimated at USD 248.66 million in 2021 and expected to reach USD 312.08 million in 2022, at a CAGR 25.27% to reach USD 961.36 million by 2027.
- The Europe, Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market size was estimated at USD 299.99 million in 2021 and expected to reach USD 374.45 million in 2022, at a CAGR 25.03% to reach USD 1,146.43 million by 2027.
Market Segmentation & Coverage:
This research report categorizes the viral vector & plasmid DNA manufacturing to forecast the revenues and analyze the trends in each of the following sub-markets:
Cell Line:
- In-vitro
- In-Vivo
Type:
- Adeno-Associated Virus
- Adenovirus
- Lentivirus
- Plasmid DNA
Transfection:
- Stable Transfection
- Transient Transfection
Indication:
- Cancer
- Genetic Disorder
- Infectious Disease
Workflow:
-
Downstream Processing
- Fill-finish
- Purification
-
Upstream Processing
- Vector Amplification & Expansion
- Vector Recovery/Harvesting
Application:
- Antisense & RNAi
- Cell Therapy
- Gene Therapy
- Vaccinology
End User:
- Biotech Companies
- Research Institutes
Region:
-
Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
-
Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
-
Europe, Middle East & Africa
- France
- Germany
- Italy
- Netherlands
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- United Arab Emirates
- United Kingdom
Company Usability Profiles:
- ABL Inc.
- Batavia Biosciences B.V.
- BioNTech IMFS GmbH
- Biovian Oy
- c-LEcta GmbH
- Cell and Gene Therapy Catapult
- Cevec Pharmaceuticals GmbH
- Cobra Biologics Limited
- Creative Biogene
- FinVector Vision Therapies
- FUJIFILM Diosynth Biotechnologies Inc.
- GE Healthcare
- GeneOne Life Science, Inc.
- Genezen Laboratories
- Kaneka Eurogentec S.A.
- Lonza Group AG
- Merck KGaA
- Miltenyi Biotec GmbH
- Novasep Inc.
- Sirion-Biotech GmbH
- Spark Therapeutics Inc.
- Thermo Fisher Scientific Inc.
- uniQure N.V.
- Vigene Biosciences, Inc.
- Wuxi AppTec Co., Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/h01txh
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
